Akèy › Kansè Metastatik › North Carolina › Durham
Etid klinik pou Kansè Metastatik nan Durham, NC
33 etid pou Kansè Metastatik ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Chapel Hill · 10 mi lwen
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Duke University Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Duke University, Durham
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Ap rekriteFaz 2/3
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Duke Cancer Center - Investigational Chemotherapy Service, Durham
- Duke Cancer Center, Durham
- Duke University Hospital - Vascular Interventional Radiology, Durham
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Ap rekriteFaz 2
- Duke Cancer Institute, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Ap rekriteFaz 2/3
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi lwen
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- Duke Cancer Institute, Durham
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- University of North Carolina Medical Center, Chapel Hill · 10 mi lwen
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · 10 mi lwen
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill · 10 mi lwen
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Duke University, Durham
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Ap rekrite
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 10 mi lwen
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Ap rekriteFaz 1
- Duke Cancer Center, Durham
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Research Site, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Duke Cancer Center, Durham
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Ap rekriteFaz 1/2
- Duke University Medical Center, Durham
UNC Childhood, Adolescent, and Young Adult Cancer Cohort
Ap rekriteEtid obsèvasyon
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
UNC Metastatic Cancer Radiation Therapy Registry
Ap rekriteEtid obsèvasyon
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · 10 mi lwen
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Ap rekriteFaz 1/2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Ap rekriteFaz 2/3
- Durham VA Medical Center, Durham, NC, Durham
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Ap rekriteFaz 2/3
- Duke University Medical Center, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Ap rekriteFaz 1/2
- Duke Cancer Center/ DUMC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- Duke Cancer Institute, Durham
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Ap rekriteFaz 3
- Duke University, Durham
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Ap rekriteEtid obsèvasyon
- Durham Veterans Administration Health Care System (DVAHCS), Durham
- Duke University Medical Center, Durham
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Ap rekriteFaz 1
- Duke Cancer Center, Durham
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Ap rekriteFaz 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- Duke University Medical Center - Duke Cancer Institute, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi lwen
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Ap rekriteFaz 3
- Duke University - Trent Center, Durham
A Study of NX-1607 in Adults With Advanced Malignancies
Ap rekriteFaz 1
- University of North Carolina, Chapel Hill · 10 mi lwen
Etid Kansè Metastatik nan lòt vil
- Houston, TX104 etid
- New York City, NY93 etid
- Nashville, TN70 etid
- Boston, MA63 etid
- Los Angeles, CA57 etid
- St. Louis, MO54 etid
- Arlington, VA53 etid
- Philadelphia, PA46 etid
- Chicago, IL45 etid
- San Antonio, TX44 etid
- Washington, DC43 etid
- Dallas, TX42 etid
Lòt etid nan Durham
- Kansè nan tete64 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Leksemi mieloïd egi33 etid
- Kansè pwostat32 etid
- Kansè poumon32 etid
- Kansè kolorektal28 etid
- Kansè ovè27 etid
- Lukemi lenfositè kwonik27 etid
- Ensifizyans kadyak26 etid
- Kansè pankreyas24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.